PMC:7536954 / 3936-4147 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T51","span":{"begin":12,"end":20},"obj":"Disease"},{"id":"T52","span":{"begin":133,"end":135},"obj":"Disease"},{"id":"T53","span":{"begin":139,"end":142},"obj":"Disease"}],"attributes":[{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A52","pred":"mondo_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/MONDO_0006559"},{"id":"A53","pred":"mondo_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/MONDO_0007915"}],"text":" during the COVID‐19 pandemic. Previous publications reported clinical improvements obtained by IL‐17A inhibition in treating either HS or SLE. 2 , 3 Secukinumab was successfully tested in an open‐label trial "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T25","span":{"begin":181,"end":187},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T26","span":{"begin":199,"end":204},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":" during the COVID‐19 pandemic. Previous publications reported clinical improvements obtained by IL‐17A inhibition in treating either HS or SLE. 2 , 3 Secukinumab was successfully tested in an open‐label trial "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T33","span":{"begin":96,"end":98},"obj":"Chemical"},{"id":"T35","span":{"begin":133,"end":135},"obj":"Chemical"},{"id":"T36","span":{"begin":199,"end":204},"obj":"Chemical"}],"attributes":[{"id":"A33","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A34","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A35","pred":"chebi_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_74056"},{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":" during the COVID‐19 pandemic. Previous publications reported clinical improvements obtained by IL‐17A inhibition in treating either HS or SLE. 2 , 3 Secukinumab was successfully tested in an open‐label trial "}

{"project":"LitCovid-PubTator","denotations":[{"id":"163","span":{"begin":96,"end":102},"obj":"Gene"},{"id":"171","span":{"begin":152,"end":163},"obj":"Chemical"},{"id":"177","span":{"begin":12,"end":20},"obj":"Disease"},{"id":"178","span":{"begin":139,"end":142},"obj":"Disease"}],"attributes":[{"id":"A163","pred":"tao:has_database_id","subj":"163","obj":"Gene:3605"},{"id":"A171","pred":"tao:has_database_id","subj":"171","obj":"MESH:C555450"},{"id":"A177","pred":"tao:has_database_id","subj":"177","obj":"MESH:C000657245"},{"id":"A178","pred":"tao:has_database_id","subj":"178","obj":"MESH:D008180"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" during the COVID‐19 pandemic. Previous publications reported clinical improvements obtained by IL‐17A inhibition in treating either HS or SLE. 2 , 3 Secukinumab was successfully tested in an open‐label trial "}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T40","span":{"begin":133,"end":135},"obj":"Phenotype"},{"id":"T41","span":{"begin":139,"end":142},"obj":"Phenotype"}],"attributes":[{"id":"A40","pred":"hp_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/HP_0040154"},{"id":"A41","pred":"hp_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/HP_0002725"}],"text":" during the COVID‐19 pandemic. Previous publications reported clinical improvements obtained by IL‐17A inhibition in treating either HS or SLE. 2 , 3 Secukinumab was successfully tested in an open‐label trial "}

{"project":"LitCovid-sentences","denotations":[{"id":"T37","span":{"begin":31,"end":143},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" during the COVID‐19 pandemic. Previous publications reported clinical improvements obtained by IL‐17A inhibition in treating either HS or SLE. 2 , 3 Secukinumab was successfully tested in an open‐label trial "}